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1. Introduction 
There are almost 6000 cases of acute lymphoblastic leukemia (ALL) diagnosed annually in 
the United States. Approximately two-thirds occur in children and adolescents making ALL 
the most common cancer in that age group.1 The remaining third occurs in the adult 
population with the incidence increasing beyond age 50. The biology of the disease with 
advancing age confers a worse prognosis than with childhood ALL as the incidence of “very 
high risk” cytogenetic categories, such as Philadelphia chromosome–positive (Ph+) ALL, is 
much higher in the older population.2 Treatment of childhood ALL has in general been 
relatively successful with five-year event-free survival rates ranging from 70 to 83% in 
developed countries, with an overall cure rate of approximately 80%. The experience with 
adult ALL has been far less successful with reported cure rates rarely exceeding 40% despite 
the use of hematopoietic stem cell transplantation (HSCT).3 Historically there have been two 
separate approaches for treatment of adult patients, transplantation-based or attempts to 
optimize chemotherapy reserving transplantation only for patients who are Ph+.4-8 Prior to 
the last decade, allogeneic transplantation in adult patients with ALL in first remission was 
reserved for patients who were Ph+ or those with advanced disease.9 The recently published 
results from the landmark UKALL XII/ECOG E2993 trial compared these treatment options 
posing the question of whether the allogeneic graft versus leukemia (GVL) effect, could 
improve the outcome for all suitable adult patients.10 The trial analysis, which will be 
discussed in detail later in the chapter, concluded that sibling donor allogeneic HSCT was 
superior to chemotherapy alone in standard risk first remission ALL patients with respect to 
overall survival. 
Achieving a complete remission (CR) with induction chemotherapy is crucial for a favorable 
outcome in adult patients with ALL. Furthermore, relapse from complete remission is 
associated with dismal survival and overall only one-third of adult patients who achieve 
complete remission will survive 5 years. Thus prevention of relapse is vital for long-term 
survival. Strategy employed to maintain remission includes autologous and allogeneic 
HSCT. In the case of allogeneic HSCT, evidence is mounting that not only related donor but 
also matched unrelated donor and umbilical cord blood sources are equivalent options 
when overall survival is considered. Historically, it was felt that both autologous and 
allogeneic transplant could improve survival on the basis of phase two data.11 More 
recently, this concept has been challenged by the findings of the UKALL XII/ECOG E2993 
trial.10 Phase two data demonstrated favorable leukemia free survival (LFS) with human 
www.intechopen.com
 
Novel Aspects in Acute Lymphoblastic Leukemia 118 
leukocyte antigen (HLA)-matched sibling allogeneic HSCT in ALL in first or later CR. 
Considering that only one-third of patients have a matched sibling donor, other graft 
alternatives have to be considered including autologous transplant (auto), matched 
unrelated donor (MUD), umbilical cord blood (UCB) and haploidentical-related donors. 
Although transplant related mortality (TRM) is low with autologous transplant, typically 
less than 5%, the overall survival (OS) is disappointing due to an unacceptably high risk of 
relapse and because of these findings, enthusiasm for autologous HSCT has decreased over 
the past few years. In contrast, the appealing aspects of allogeneic transplantation, including 
the potential for an immune mediated GVL effect has been associated with decreased 
relapse rates and improved LFS.11 
2. Graft versus leukemia 
The GVL effect in recipients of allogeneic HSCT is an anecdotally described and statistically 
demonstrated phenomenon. The GVL effect is statistically evident by demonstration of a 
higher relapse rate after autologous or syngeneic HSCT compared to allogeneic HSCT. 
There is also a lower incidence of relapse in patients who experience graft versus host 
disease (GVHD), as well as increased relapse rates in recipients of T-cell-depleted marrow 
grafts. Both single institution and registry data provide evidence of an allogeneic GVL effect 
with relapse rates lower in patients who developed GVHD than in those who did not.12, 13 
The occurrence of acute, chronic or both forms of GVHD correlated with the best disease 
free survival (DFS).  
Doney and colleagues described a study of 192 patients with ALL, mostly transplanted in 
second remission (CR2). They evaluated the probability of relapse among patients with or 
without GVHD.12 Relapse was significantly higher in the group that had grade 0-I GVHD. In 
fact, in patients without significant GVHD, the actuarial risk of relapse approached 80% 
versus 40% in those who developed grade II or above. Subsequently, this observation was 
confirmed for both relapse and overall DFS by Appelbaum et al.13 Passweg reported a study 
of 1132 patients with T-cell or B-cell ALL, which showed a decreased rate of relapse in 
patients with both acute and chronic GVHD.14 
These data support the idea that T-cells in the graft mediate a potent GVL effect in patients 
with ALL. Augmenting the GVL effect may be possible by developing antigen-specific T-cell 
immunotherapy for patients with ALL.13, 15-18 
3. Minimal residual disease 
As mentioned previously, one of the most important prognostic factors in patients with 
ALL is the achievement of CR after induction chemotherapy, in addition to age and 
cytogenetic abnormalities at the time of diagnosis. These factors directly reflect the 
chemosensitivity of the disease. Consequently, a longer time to achieve CR during induction 
is an indicator of relative chemoresistance. Several studies have shown that patients who 
need more than one cycle of induction chemotherapy have a poor long-term prognosis and 
a shorter duration of remission.19-21 Historically, clinical trials have defined success of 
induction chemotherapeutic regimens on the basis of morphology. 
With the advent of ever more sensitive molecular and immunophenotypical methods, a 
single blast cell in 10,000 normal cells can now be reliably detected. Using these techniques a 
majority of patients with ALL will have markers identified that can be used to detect 
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minimal residual disease (MRD) at different times throughout the treatment course. The 
presence of MRD as detected by these methods allows for the identification of groups at risk 
for relapse. MRD studies might be useful for identifying high-risk groups of patients who 
might benefit from early transplantation and also provide guidance to help determine the 
most suitable conditioning regimen.22 
Bassan and colleagues reported results of the Northern Italy Leukemia Group (NILG) 
study 09/00 of 280 patients with ALL. Adequate probes for MRD detection were obtained 
in 223 patients (88%) with a single marker in 61% and two probes in 39%.23 A sensitivity 
level of 10-4 or higher was found in 94% of these patients and data was available on 79% of 
patients who completed the first stage of treatment. The presence of MRD was the 
strongest predictor of LFS and bone marrow relapse in the multivariate model used. 
Detection of MRD was associated with hazard ratios of 5.88 for DFS and 5.33 for bone 
marrow relapse (p=0.001). The study used risk-adapted therapy based upon MRD 
detection. 
 
 
 
Table 1. Clinical Significance of MRD Analysis in Adult ALL (selection of recent 
representative studies, mainly Ph- patients) 
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In an earlier study by the German study group GMALL, 196 patients with standard risk-
ALL had their MRD status monitored prospectively.24 At week 16 of therapy, subsets of 
patients could be identified with very different outcomes. Twenty three percent of patients 
who had MRD detectable until week 16 and beyond had a 3-year relapse rate of 94% 
whereas no relapses occurred in 10% of the patients who had a rapid decline to undetectable 
levels when measured at days 11 and 24. Other studies have also shown similar trends 
(Table 1). 
Studies in MRD have also been performed in the pediatric population. A recent study used 
polymerase chain reaction (PCR) amplification of antigen-receptor genes to detect 1 
leukemic cell per 100,000 normal mononuclear cells (0.001%).25 Stow and colleagues 
examined 455 pediatric patients and compared 2 cohorts based on MRD levels at day 46 of 
therapy. Those patients with MRD < 0.001% had a 5 year risk of relapse of 5% compared 
with 13% for those with MRD levels of < 0.01% but > 0.001% (p < 0.047). 
These studies show that a higher level of MRD either after consolidation chemotherapy or a 
rising level during treatment might predict for a higher relapse rate. Inversely, a low level of 
MRD might identify a group of patients who do not necessarily need transplantation, or 
perhaps can wait until there is clear evidence of rising levels of MRD before further therapy 
is initiated.24, 26-28 In the future, MRD might be used to further refine the treatment options 
for patients with ALL, and may better define which patients should undergo 
transplantation. 
4. Who should receive a HSCT? 
Established predictors of poor long-term outcome in ALL patients undergoing aggressive 
chemotherapy have been used to determine which patients should proceed to 
transplantation in first remission. In the pediatric population, transplantation is reserved for 
the patients with the worst prognosis, whereas the adult patient is much more likely to 
benefit from allogeneic HSCT and the procedure is performed more frequently. Patients 
with high risk features are known to have a greater risk of relapse and have historically 
undergone HSCT in first remission (CR1) if they were deemed transplant candidates.19, 29-31 
High-risk features include: age greater than 35 years, leukocyte count > 30,000/µL for B-cell 
and > 100,000/µL in T-cell origin, non T-cell phenotype, lack of mediastinal adenopathy, 
poor performance status at diagnosis, t(9;22), t(4;11), t(1;19) or t(8;14). Patients who require 
more than four weeks of induction therapy to achieve remission or who have detectable 
molecular or immunophenotypical evidence of disease while in remission also have a 
poorer prognosis.32 
The results of the UKALL XII/ ECOG E2993 trial demonstrated superior survival in 
standard risk patients who underwent allogeneic HSCT. Many centers have taken this as 
conclusive evidence that all patients with standard risk disease in CR 1 should undergo 
allogeneic HSCT, if they are suitable candidates and a suitable donor is available.10 Whether 
allogeneic transplant should be performed in all ALL patients in CR 1 is debatable, given the 
excellent outcome observed with chemotherapy alone in subsets such as young males with 
standard risk T-ALL. The reduction of relapse risk with allogeneic HSCT is definitely 
superior to chemotherapy alone or autologous transplant.5, 10, 33-37 Given the uncertainty, 
patient education and choice must be a priority for clinicians who treat such individuals. 
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Adolescents and young adults (AYA), ages 16-30, or subsets thereof appear to have less 
favorable outcome than younger pediatric patients. However, retrospective analyses 
comparing pediatric and adult therapy of ALL in AYA, have shown significantly better 
results with pediatric treatment protocols with survival rates at 5 years of 67% to 78% 
compared to 34% to 41% with adult protocols.36, 38-42 The question of the applicability of 
pediatric style therapy is being formally tested in clinical trial to define the toxicity and 
feasibility of the pediatric approach to therapy in AYA. The CALGB is conducting study 
10403 (http://www.clinicaltrials.gov ID:NCT00558519), which treats ALL patients 16 to 
39 years of age on one arm of the Children's Oncology Group (COG) AALL0232 protocol. 
As the CALGB and COG protocols are running concurrently patient specific data from 
both trials will be used to compare the outcome of AYA treated in the pediatric and adult 
settings. Investigators at the Dana Farber Cancer Institute are conducting a phase 2 
clinical trial that investigates the safety and efficacy of a pediatric regimen which includes 
pegylated L-asparaginase in patients age 18-50 (Study 06-254).22 If the outcome appears to 
be improved by the application of the pediatric approach to therapy of ALL then 
subsequent trials might compare allogeneic transplant to pediatric chemotherapy 
regimens in a prospective fashion. 
Although pediatric style treatment when retrospectively compared to adult therapy has 
created an interesting hypothesis, the UKALL XII/ECOG E2993 trial showed that in every 
age group up to 40 years, including those younger than 20, there was an OS advantage to 
having a donor. There is thus insufficient evidence at this point to conclude that allogeneic 
transplantation in CR1 should be abandoned in this age group, including those with high-
risk disease.22 
In patients with ALL greater than 50 years of age, treatment related mortality increases and 
the effectiveness of therapy decreases, as noted in previous studies and the UKALL 
XII/ECOG E2993 trial. The age at which the TRM exceeds the reduction in relapse risk may 
even be as low as age 35 to 40 years. A recent meta-analysis that included the UKALL 
XII/ECOG E2993 data also showed a survival advantage for standard risk patients and a 
non-significant survival advantage for high-risk patients.43 This may be due in part to the 
fact that older patients have more high-risk features. These prospective trials have used full-
intensity myeloablative conditioning regimens that include total body irradiation (TBI), 
whereas reduced intensity conditioning (RIC) might allow for the therapeutic benefit of a 
GVL effect with less transplant related toxicity. Reduced TRM with RIC regimens might 
permit allogeneic transplantation in older patients.22 Conditioning regimens, including RIC 
regimens, are reviewed in more detail later in the chapter. 
In patients with B-ALL that express CD20, the addition of the anti-CD20 monoclonal 
antibody rituximab to chemotherapy, might increase the survival rate by 20% to 30% to 
approximately 80%.44, 45 In these patients, relapse tends to occur within the first year and a 
half after achieving remission. There are no validated prognostic factors that predict relapse. 
Thus the detection of MRD in CR1 might select patients for allogeneic HSCT since 
maintenance chemotherapy is associated with a high risk of relapse.33 
Until more effective non-transplant therapy is developed for adult ALL, risk adapted 
selection of patients for allogeneic HSCT will likely increase. The co-morbid status, age of 
the patient and MRD status will most likely dictate the type of conditioning regimen 
selected for transplantation.10 A summary of overall results of HSCT in adults with ALL can 
be found in table 2. 
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Table 2. Overall Results of HSCT in Adult ALL and Current Recommendations 
5. Types of HSCT 
Since 2000, there have been at least 10 trials that have compared the outcome of patients 
with ALL with high-risk features based upon related donor availability. 4, 7, 46, 47 Seven out of 
ten studies demonstrated statistically significant improvement in LFS with allografts. TRM 
varied considerably between 9% and 44% with the highest reported in the LALA-87 trial in 
sibling donor allogeneic HSCT compared to 2% to 24% in autologous transplant.7 A meta-
analysis was performed of all prospective trials, 1274 total patients, which confirmed a 
beneficial effect of allogeneic sibling HSCT.48 Patients in the sibling donor group showed 
better survival, which was even more pronounced in the patients with high-risk features. 
The UKALL XII/ECOG E2993 trial reported its findings to prospectively determine what 
the optimal therapy should be for adult patients with newly diagnosed ALL. In individuals 
with standard risk ALL, defined as age < 30 years, Philadelphia chromosome negative and 
low white blood cell count at presentation, OS in allogeneic HSCT recipients was found to 
be superior to chemotherapy in CR1. The greatest benefit was apparent in patients < 30 
years as higher TRM negated the benefit of a lower relapse rate in older patients. 
HLA-matched unrelated donor transplantation is another HSCT option for patients with 
ALL. In high-risk ALL, matched unrelated donors have been used when matched siblings 
were not available, and there is preliminary evidence that a well-matched unrelated donor 
may be comparable to a sibling donor.49 There have been no prospective randomized trials 
that investigate the use of this type of transplant compared to autologous transplant. In a 
large retrospective analysis from the Center for International Bone Marrow Transplant 
research (CIBMTR), outcome and toxicity of 712 patients < 50 years of age in CR1 or CR2 
were compared based upon type of HSCT (517 MUD, 195 autologous).50 TRM was 
significantly higher in the MUD treatment group as compared to those patients who 
underwent autologous transplant (p=0.004). The CIBMTR also performed a long-term 
update analysis that confirmed similar 5-year survival for patients in CR1 after MUD and 
autologous transplant (38% versus 39%), but superior 5-year survival after MUD 
transplantation in CR2 (30% versus 14%).11 The rate of relapse was significantly different 
between the two types of transplant: 20% in CR1 and 25% in ≥ CR2 for MUD versus 58% in 
CR1 and 81% in ≥ CR2 in autologous transplant (P=<0.0001). 
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There have been two recent studies that compared the outcomes of MUD and sibling 
allogeneic transplantation.8, 51 In these studies, HLA class I and II high resolution typing was 
used for most of the patients, which reflects more closely the current standard of donor 
selection. The first study found that disease free survival (DFS) for adults with high-risk 
ALL in CR1 is similar between siblings and MUD HSCT. The second study included 84 
high-risk patients and showed a 3-year survival of 46% in patients who received a sibling 
allogeneic transplant versus 44% for those treated with MUD transplantation. There was no 
relevant difference noted in TRM rate (27% and 26%, respectively). These reports support 
comparable results whether the allogeneic donor is related or unrelated. Recent reports that 
present comparable outcomes after related and unrelated HSCT are not based on intention-
to-treat analyses and need to be interpreted appropriately. Despite the widespread 
perception of a similar outcome, it is common practice for a discrepant approach in the 
policy of many transplant centers.9 
Umbilical cord blood (UCB) transplantation is now a standard option for management of 
pediatric ALL. UCB grafts that are partially mismatched have been used without causing 
excessive GVHD or graft rejection. This may be a consequence of the naïve immune status of 
T-cells in the UCB unit. Collection of UCB from ethnic and racially underrepresented 
populations in the donor pool might increase the availability of allogeneic HSCT as a 
treatment option for these groups.11 Since the collection of UCB is possible from every 
healthy live birth with no potential harm to the donor, this option is potentially unlimited as 
donation is uncomplicated. UCB samples are also prescreened for infection, HLA-typed and 
cryopreserved and are thus quickly available for transplantation. Three studies examined 
UCB transplantation in adults with different types of hematological malignancy and a meta-
analysis was performed.52 There were 316 total adults who received UCB transplant versus 
996 patients who underwent mostly fully matched unrelated donor transplantation without 
in vitro T-cell depletion. The TRM and DFS were not statistically different between the two 
groups despite more HLA-disparity in the UCB transplant patients. This meta-analysis 
represents the most cogent data available for comparison of UCB and MUD transplantation. 
Logistical difficulty associated with designing and conducting a randomized comparison of 
UCB and MUD transplantation makes this comparison unlikely in the future. 
Mismatched related donor and haploidentical HSCT is an experimental therapy whose 
usefulness is being explored in patients with very high-risk and late stage disease who do 
not have an HLA-matched sibling or alternative donor available.22 The advantage of 
haploidentical HSCT is both real and theoretical. The most obvious advantage is the almost 
universal availability of a related donor who is at least haplotype identical to the patient in 
need of the transplant. Such donors are usually available quickly, and can serve as repeat 
donors in the event of engraftment failure or as donors of lymphocytes in order to convert 
mixed chimerism to full donor hematopoiesis or to treat disease relapse. A more potent graft 
versus tumor effect is also a theoretically attractive benefit from this type of transplant.53 
6. Why Allogeneic HSCT? 
6.1 UKALL XII/ECOG E2993 
In 1993, the UK Medical Research Council (MRC) and the Eastern Cooperative Oncology 
Group (ECOG) of the United States collaboratively developed a large study to ask two 
fundamental questions regarding ALL.10 Given that GVL was first described in adult ALL 
and given published data supporting allogeneic transplantation in first CR for Ph+ and 
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other high risk patients; could the allogeneic effect improve the outcome for all suitable 
adult patients?8, 54 The second question was, given the fact that protracted 
consolidation/maintenance therapy has been the mainstay of treatment for ALL, based on 
data mostly extrapolated from pediatric experience, could single autologous transplantation 
replace extended maintenance therapy? The UKALL XII/ECOG E2993 trial was designed so 
that all adult patients with a matched sibling donor would receive an allogeneic HSCT. The 
patients without a donor would be randomized to an autologous HSCT versus 
consolidation and maintenance chemotherapy. Maintenance therapy consisted of vincristine 
1.4 mg/m2 intravenously every 3 months, prednisone 60 mg/m2 orally for 5 days every 3 
months, 6-mercaptopurine 75 mg/m2 orally each day, and methotrexate 20 mg/m2 orally or 
intravenously once a week. Maintenance therapy was to continue for a total of 2.5 years 
from the start of intensification therapy. 
Prior to randomization, all patients received intensification with high dose methotrexate. 
The primary outcome of the study was OS. Other measures of outcome to be assessed were 
event free survival (EFS) and non-relapse mortality defined as time to death censored at 
relapse. 
A total of 1929 patients were recruited from 1993 to 2006, with 16 excluded, as pathology 
review did not substantiate the diagnosis of ALL. All patients age 15-59 with newly 
diagnosed ALL were included, including Ph+ patients. They received identical induction 
therapy, irrespective of risk assessment, including central nervous system (CNS) 
prophylaxis and treatment of CNS disease if present at diagnosis. In 2003, the upper age 
limit was increased to 64 and the upper age limit for allogeneic transplant was increased to 
54. Patients that were Ph+ were also offered MUD transplantation. 
High risk in this study was defined as patients older than 35 years, having a high WBC 
count at diagnosis (≥ 30 x109/L for B lineage and ≥ 100 x 109 /L for T lineage) and patients 
with t(9;22). All other patients were deemed standard risk. The median follow-up in this 
study was 4 years, 11 months. The OS of the 1913 patients at 5 years was 39% and was 43% 
for patients who were Ph- (Figure 1A and 1B) and there was no difference in survival 
between patients entered through MRC or ECOG (Figure 1C). Figure 1D demonstrates the 
overall survival benefit when all patients on study are included in this analysis with a 5-year 
survival of 53% (95% CI = 48% - 58%) for patients with a donor versus 45% (95% CI = 40% - 
49%) for patients without a donor (p = 0.1). The high-risk patients had an OS of 41% versus 
35% for donor versus no donor, respectively, which was not statistically significant; 
however, the OS was significantly improved in the standard risk patients, 62% versus 52% 
for donor versus no donor, respectively (p = 0.02) for survival at 5 years (Figure 1E and 1F). 
The relapse rate was significantly reduced in both risk groups who underwent allogeneic 
HSCT, confirming the potency of the graft versus leukemia effect in allogeneic 
transplantation. 
There were 456 patients in the study that were randomized to the chemotherapy versus 
autologous transplantation arm of which 16 were Ph+. The patients who were randomized 
to receive chemotherapy had significantly improved 5 year EFS (41% versus 32%; p = 0.02) 
and OS (46% versus 37%; p = 0.03) (Figure 2A and 2B). The 5-year survival for 
chemotherapy versus autologous transplantation among the high-risk patients was 37% 
versus 31%, respectively and was 56% versus 46%, respectively for the standard risk 
patients (Figure 2C and 2D). Non-relapse mortality was 16% for the autologous versus 8% 
for the chemotherapy group (Figure 2E). 
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Note: Adapted from Goldstone, et al.10 
Fig. 1. Survival of patients and donor versus no-donor analysis. Overall survival from 
diagnosis for (A) all patients entered on the study, including Ph-positive; (B) Ph-negative 
and Ph-positive patients; (C) patients entered via MRC or ECOG; (D) donor versus no-
donor for all Ph-negative patients; (E) donor versus no-donor for Ph-negative patients with 
high risk; and (F) donor versus no-donor for Ph-negative patients with standard risk. 
After reviewing the data and noting that patients randomized to chemotherapy had a better 
outcome than those undergoing autologous transplantation, an analysis was made that 
compared patients with a donor versus those without to investigate the effect of allogeneic 
transplantation versus chemotherapy alone. There was a superior OS noted for the patients 
with a donor, in the standard risk patients, with a 5-year survival of 62% for those with a 
donor versus 52% for those without. This same benefit could not be demonstrated for the 
high-risk patients. In high-risk patients, the donor versus no donor comparison showed a 5 
year OS of 41% versus 35% which was not statistically significant. This finding questions the 
need for immediate allogeneic transplantation in high-risk patients, however for high-risk 
patients allogeneic transplantation remains the standard of care. 
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Note: Adapted from Goldstone, et al.10 
Fig. 2. Randomized chemotherapy versus autologous transplantation, measured 
from time of randomization. (A) Event-free survival for all patients. (B) Overall survival 
for all (C) high-risk patients and (D) standard-risk patients. (E) Nonrelapse mortality for 
all patients undergoing chemotherapy or autologous transplantation. 
One of the most noteworthy findings of the UKALL XII/ECOG E2993 trial was the potent 
anti-leukemic effect seen in adults who received allogeneic transplantation as demonstrated 
by a significantly reduced relapse rate. TRM in the high-risk patients was 36%, which is 
considered to be unacceptably high. In the low-risk group with a donor the TRM was 20%. 
However the high-risk group was older than the standard-risk group and would be 
expected to suffer more TRM. The TRM in the standard-risk group was 7% for no donor but 
rose to 14% in the high-risk group with no donor. The most benefit was seen in patients with 
standard risk disease where allogeneic transplant demonstrated a significant survival 
advantage over those who underwent conventional chemotherapy (Figure 3A, 3B and 3C). 
There have been small studies of autologous transplantation reported.4-7, 55 Review of the 
data shows no clearly increased anti-leukemic benefit over conventional chemotherapy. The 
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UKALL XII/ECOG E2993 trial showed an inferior outcome for autologous transplantation 
as compared to chemotherapy and thus autologous HSCT cannot be recommended as the 
preferred modality. The study concluded that allogeneic transplantation is the treatment of 
choice for adults with standard risk disease in remission and provides the greatest chance 
for long-term survival. 
 
 
Note: Adapted from Goldstone, et al.10 
Fig. 3. Relapse on study and mortality not associated with relapse. Relapse rate for (A) Ph-
negative patients at standard risk; (B) Ph-negative patients at high risk; and (C) nonrelapse 
mortality for high-risk and standard-risk patients. Note the underlying mortality at 1 and 2 
years among the no-donor group. 
7. Philadelphia positive ALL 
ALL with t(9;22), also referred to as Philadelphia chromosome positive (Ph+), historically 
has a lower rate of CR and lower long-term OS than Ph negative disease. Ph+ ALL accounts 
for approximately one fourth of all adult ALL. Historically, clinical trials typically would 
assign this group to the very-high-risk treatment arms and most physicians treating outside 
of a clinical trial would recommend myeloablative HSCT. With the advent of tyrosine kinase 
inhibitors (TKI), there is now the question of whether HSCT is still necessary in this patient 
population.49 There have been two large studies performed that support the overall benefit 
of a sibling transplant in unselected patients with Ph+ ALL in the pre-TKI era. The first 
study was the LALA-94 trial that prospectively studied 154 patients with Ph+ ALL and 
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showed that among 103 patients eligible for HSCT, the presence of a sibling donor was 
independently predictive of remission duration.47 The second trial, the previously 
mentioned UKALL XII/ECOG E2993 study, evaluated the outcome of 267 patients with Ph+ 
ALL and noted that those patients who had received a myeloablative sibling allogeneic or 
MUD transplantation had a better outcome than those who had received chemotherapy 
alone.56 
There are no prospective randomized trials reported to date that use reduced intensity 
conditioning (RIC) in patients with Ph+ ALL. Investigators at the City of Hope Medical 
Center reported 24 adult patients with high-risk ALL treated with fludarabine and 
melphalan conditioning without T cell depletion with nearly half of the patients being over 
age 50. They found a 2-year OS and DFS of 62 percent with TRM of 22%.57 There was 
another case series from the University of Minnesota Transplant program that reported a 3-
year OS of 50% among 22 patients with a median age of 49 years, all with high-risk ALL 
treated with a RIC regimen of fludarabine, cyclophosphamide and low dose total body 
irradiation (TBI).58 These studies show non-myeloablative regimens to be promising, but 
require careful prospective studies to define their role in Ph+ ALL. The UK National Cancer 
Research Institute, UKALL XIV, will assign all patients with ALL over the age of 40 to a 
non-myeloablative approach with fludarabine, melphalan and alemtuzumab in an attempt 
to decrease GVHD, which was seen in 86% of the City of Hope patients who did not 
undergo T cell depletion as part of their conditioning regimen.49 
Prospective studies that randomize between allogeneic HSCT and continued chemotherapy 
introduce complexity in the analysis and interpretation of the trial data. Specifically the 
analysis might be biased by survivor treatment selection bias, also known as immortal time 
bias. Simply, patients with Ph+ ALL on a prospective study who undergo HSCT must have 
achieved, and remained in, a CR before transplant, resulting in a period of “immortal time.” 
Patients dying of either disease or treatment-related causes within the immortal time 
window are never transplanted, resulting in an immortal time bias. This type of bias is 
present in studies of Ph+ ALL due to the lower rates of CR, short remission duration and 
toxicity of the initial treatment, as compared to Ph- patients.49 The overall effect is to 
overestimate the effect of allogeneic HSCT as compared to chemotherapy when analyzed in 
an intent-to-treat fashion. The UKALL XII/ECOG E2993 trial is a good example of how the 
potential benefits of HSCT can be overestimated. Analysis by treatment received showed 
that those who received either a sibling or MUD HSCT had a much better 5-year OS (44% 
and 36%) than those who had received chemotherapy alone (19% at 5 years). All of these 
results, in addition to EFS and relapse free survival (RFS) were highly statistically 
significant. In contrast, when the analysis was repeated, adjusting for age, sex, presenting 
WBC and chemotherapy-treated patients who relapsed or died before median time to 
transplant were excluded; only RFS remained significantly superior in the transplanted 
group.49 
Childhood ALL with t(9;22) remains an indication for HSCT. Due to the rarity of the disease, 
only 2% of cases, studies have been difficult to carry out. The Children’s Oncology Group 
conducted a study using imatinib with intensive chemotherapy.59 The study evaluated 92 
patients ages 1-21 who were divided into 5 cohorts who received progressively increased 
exposure to imatinib from 42 days to 280 continuous days (cohort 5, n=50) before maintenance 
therapy. Patients with an HLA identical sibling underwent HSCT with imatinib given for 6 
months following their transplant. This allowed for comparison between the group that did 
www.intechopen.com
 
Cellular Therapy of ALL 129 
not undergo transplantation and only received chemotherapy in combination, to the group 
that eventually went on to transplant. The concluding data was slightly confounded by the 
relatively high rate of off protocol use of MUD HSCT. Nevertheless, at 3 years, the outcomes 
were not significantly different for those treated with chemotherapy plus imatinib (n=25) 
compared to those treated with allogeneic HSCT (n=21). More than 85% of patients were alive 
and disease free at 3 years without allogeneic HSCT. This study was not powered to answer 
the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in 
Ph+ ALL, but the results encourage further investigation. 
The UKALL XII/ECOG E2993 trial also reported in abstract form a large cohort of patients 
who were treated with imatinib and chemotherapy who did not undergo HSCT, in which 
the 3 year OS was 28%. By comparison, the 5 year OS of historical controls in the pre-TKI era 
was 19%.60, 61 
A small series reported by Thomas et al added imatinib to hyper-CVAD induction 
chemotherapy and concluded superiority over historical controls treated with 
chemotherapy alone.62  In older patients, for whom HSCT is not an option due to the 
presence of co-morbid conditions, the efficacy of imatinib alone can be studied more clearly. 
In a German study that included patients over 55 years of age (median 68 years), patients 
were randomized between co-administration of imatinib with induction chemotherapy or 
subsequent co-administration with consolidation chemotherapy.61 The CR rates were 96% 
and 50%, respectively; however, there was no significant difference between the 2 cohorts in 
OS. Only 43% of the patients had undetectable BCR-ABL transcripts. Patients negative by 
reverse transcriptase polymerase chain retention assay (RT-PCR) for BCR-ABL had superior 
OS compared to those who remained positive.2 
In other studies imatinib was given as monotherapy without subsequent HSCT, but the 
majority of those patients were older. These studies have shown similar impressive initial 
responses to that seen in the younger patients. CR rates of 90% to 100% have been 
documented, however relapse occurs quickly and long-term DFS remains low.60, 61 A 
substantial number of patients treated with imatinib develop resistance which accounts for 
the high number of relapses. Second generation TKIs, such as dasatinib and nilotinib, have 
demonstrated promising efficacy in treatment of patients with imatinib resistance.63-65 Long 
term survival however, remains elusive with monotherapy. 
The CALGB has conducted a clinical trial (study 10001) to determine the activity and 
tolerability of imatinib used in initial treatment of Ph+ ALL. In that trial, imatinib is 
administered after sequential chemotherapy. Subsequently patients underwent autologous 
HSCT, allogeneic HSCT or consolidation chemotherapy with Etoposide and Cytarabine. All 
patients were given imatinib maintenance therapy beginning on day 30 post transplant or 
after consolidation chemotherapy and were continued on treatment for at least 1 year. 
Therapy was stopped before 1 year if the patient had 2 consecutive negative RT-PCR at least 
3 months apart or until relapse. The final results of this study are not yet available and 
accrual closed April 2010 (https://www.clinicaltrials. gov ID:NCT00039377). Other trials 
compared alternating blocks of chemotherapy with single agent imatinib versus a 
concurrent treatment regimen. The simultaneous treatment schedule did induce greater 
reductions in the BCR-ABL transcripts than the alternating schedule (p = 0.01), however 
there was no significant improvement in overall survival.66 
For patients with Ph+ ALL, myeloablative HSCT is still the treatment of choice if the patient 
is able to tolerate the procedure. There is a lack of prospective data showing TKIs alone or in 
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combination with chemotherapy, have increased survival in ALL. Whether the 
incorporation of TKIs into the treatment of Ph+ ALL will increase the efficacy of allogeneic 
HSCT remains an open question. If TKI therapeutics were to be administered early in the 
treatment of Ph+ ALL, this strategy might facilitate allogeneic HSCT if CR is improved and 
extended. The use of TKI therapy after allogeneic HSCT might provide sufficient post-
transplant leukemia suppression to allow a GVL effect to develop. In those patients with 
persistent MRD after transplant the GVL might be more potent with TKI suppression of 
MRD. 
8. Conditioning regimens 
Conditioning regimens previously employed in the treatment of ALL range from the fully 
myeloablative TBI containing regimens to the RIC regimens. Novel methods of radiation 
administration such as tomotherapy and radioimmunoconjugates are under clinical 
investigation. 
8.1 Myeloablative conditioning regimens 
Although many different regimens have been developed for ALL, the one most commonly 
used is cyclophosphamide (Cy) plus TBI.32 TBI has remained the backbone of conditioning 
regimens for ALL since the decade beginning 1970. It is prudent to understand the details of 
TBI with respect to DFS and TRM and how the patient population under treatment 
influences these statistics. 
8.2 Role of TBI 
Initially, TBI was intended for eradication of disease or to reduce the tumor burden.67-69 
After TBI was established as a myeloablative agent in the setting of autologous and 
allogeneic transplantation, several groups also recognized its potential role as an 
immunosuppressive agent.70 TBI can be employed as an immunosuppressant, facilitating 
engraftment of donor cells and allowing for an immunotherapeutic effect of donor cells 
against ALL. In this role, TBI is not used for its myeloablative properties.  
Early myeloablative regimens employed TBI as single doses of 8-10 Gray (Gy).67-69 These 
large dosages of radiation resulted in significant morbidity and mortality, particularly from 
interstitial pneumonitis.71, 72 In order to decrease toxicity and improve tolerability, 
fractionation and dose rate reduction were employed.72-76 Studies in both rodents and 
humans indicated that rates less than 10-12 cGy/min were associated with reduced 
morbidity.73, 77, 78 Other studies showed that fractionated TBI given daily or even up to four 
times daily improved the therapeutic ratio, thus allowing for higher doses of radiation to be 
delivered safely.68, 77, 79, 80 These data support reduced dose-rate, fractionated TBI as standard 
and myeloablative regimens containing TBI commonly employ a schedule delivering 12 Gy 
TBI administered twice daily in six fractions over three days (200 cGy per fraction), in 
combination with chemotherapy. These regimens provide both immunosuppressive and 
cytotoxic activity. Dose escalation to 15-16 Gy in hopes of further reducing relapse rates has 
not been shown to improve overall survival. Although relapse rates did decrease, there was 
an increase in non-relapse mortality, thus offsetting any benefit from the higher dose of 
TBI.79, 81, 82 
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8.3 Cy/TBI versus BuCy 
Investigators substituted Busulfan (Bu) for TBI creating the regimen BuCy as some centers 
did not have TBI available.83, 84 These studies showed that combined alkylating agents could 
replace Cy/TBI as conditioning for HSCT in the treatment of ALL. 
There is conflicting data on the superiority of one regimen over another and various studies 
have tried to answer this question. A retrospective analysis from the CIBMTR concluded 
that the Cy/TBI regimen was superior to the non-TBI-containing regimen of BuCy, with a 3-
year survival of 55% versus 40% for BuCy (P = 0.003). The study also found that the risk for 
relapse was similar between the groups.85 A more recent meta-analysis of seven randomized 
controlled trials involving 730 patients compared Cy/TBI to BuCy in patients with acute 
leukemia and found that Cy/TBI was associated with a modest but non-significant 
reduction in all cause mortality (RR = 0.82, 95%CI: 0.64-1.05; p = 0.12) and relapse of 
leukemia (RR = 0.89, 95%CI: 0.72-1.10; p = 0.28). Treatment related mortality was 
significantly less with Cy/TBI compared to BuCy (RR-0.53, 95%CI: 0.31-0.90; p = 0.02) but 
the cumulative incidence of major complications was not significantly different between the 
two regimens.86 
8.4 Other regimens 
Several centers have employed high-dose fractionated TBI in combination with high-dose 
Ara-C in patients receiving allogeneic HSCT from sibling donors, and have not shown any 
significant improvement in DFS, except for a small series of pediatric patients in one 
study.87, 88 Another study looked at combining Busulfan, Fludarabine and 400 cGy of TBI as 
a myeloablative regimen and showed low transplant-related mortality of 3% and projected 
DFS of 65%.89 Significant interest has also been shown in evaluating the role of etoposide as 
part of conditioning regimens including a phase I/II study that evaluated substituting 
etoposide for Cyclophosphamide in combination with fractionated TBI (13.2Gy). This study 
found DFS to be 57% with a 32% relapse rate suggesting that this regimen had significant 
activity in patients with advanced ALL.90 A subsequent randomized controlled trial also 
confirmed these findings.91 The UKALL XII/ECOG E2993 trial utilized Etoposide/TBI as 
their conditioning regimen for patients with ALL in CR1. Another study that compared 
Cy/TBI to Etoposide/TBI (60mg/kg) in 502 patients with ALL found that relapse rates, 
treatment failure and mortality were lower with etoposide/TBI, regardless of TBI dose 
(P=0.001).92 However, in patients receiving Cy/TBI, OS was significantly improved with TBI 
doses less than 13 Gy (p = 0.0005). 
We conclude that both the chemotherapeutic agents used, as well as the dose of radiation 
therapy, interact in altering the outcome of patients with ALL undergoing HSCT. There is 
still no conclusive evidence of one regimen’s superiority over another but most centers are 
still inclined to include TBI as part of any regimen used for myeloablative conditioning in 
patients with ALL. 
8.5 Role of reduced intensity conditioning 
As mentioned previously, the UKALL XII/ECOG E2993 trial showed that allogeneic HSCT 
confers the greatest durable benefit for standard risk adult patients and is more effective 
than either chemotherapy or autologous HSCT.10 However, the same trial also showed that 
in patients over 45 years of age and others with high-risk ALL, a high non-relapse mortality 
(NRM) of 36% would offset any potential survival advantage of a reduced relapse rate 
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conferred by myeloablative transplant. Thus, myeloablative regimens are often limited to 
patients who are less than 50 years of age and have an excellent performance status. RIC 
regimens have been developed over the last decade to allow engraftment with reduced 
regimen related toxicity. Once donor engraftment is achieved and immune reconstitution 
has started a GVL effect might be operative. Hence the benefit of allogeneic transplantation 
might be retained and with decreased regimen related toxicity this type of transplant could 
be offered to older patients with greater safety. 
Investigation of RIC in ALL has somewhat lagged behind studies of other hematological 
malignancies such as AML, despite evidence of a GVL effect.93 Gyurkocza and collaborators 
reported 247 patients with AML with a median age of 60 who underwent allogeneic HSCT 
from both related as well as unrelated donors.94 The estimated OS at 5 years was 33% and 
the estimated 5-year relapse/progression rate and non-relapse mortality were 42% and 26%, 
respectively.  
There have been several reports published with regards to using RIC in adult patients with 
ALL. One series of 24 patients, primarily with high risk ALL, who received Fludarabine and 
Melphalan conditioning, followed by matched related (33%) or unrelated (67%) HSCT.57 
Only 10 patients in the series were in CR1 and there was a median follow-up of 28.5 months 
for living patients. Both OS and DFS at 2 years was 62%, relapse incidence was 21% and 
non-relapse mortality was 22% at two years. 
The European Group for Blood and Marrow Transplantation (EBMT) reported the outcome 
of 97 adult patients with ALL who received RIC allogeneic HSCT.95 Only 29% of patients 
were in CR1 and the 2-year OS for this sub-group was 52%. Inclusive of all patients, the 2-
year OS was 31% with a non-relapse mortality of 18%. Marks et al reported 93 adult patients 
with Philadelphia negative ALL receiving RIC allogeneic HSCT compared to 1428 patients 
receiving full-intensity allografts using sibling and unrelated donors in first or second CR.96 
Surprisingly, the RIC cohort had a similar OS to the full intensity cohort at 3 years (38% 
versus 43%, p = 0.39) despite a substantially older median age (45 versus 28, p < 0.01). 
A retrospective study reported by the EBMT compared the outcome of 576 adult ALL 
patients aged 45 and over in CR who received RIC (n=127) or full intensity conditioning 
(n=449) followed by allogeneic HSCT from an HLA-identical sibling.97 With a median 
follow-up of 16 months, the non-relapse mortality was significantly higher in the cohort of 
patients receiving the full intensity conditioning while rates of relapse were significantly 
higher in the RIC cohort. In a multivariate analysis, the type of conditioning regimen was 
not significantly associated with leukemia-free survival. 
Ram et al evaluated the utility of RIC in patients with high-risk ALL.98 Fifty-one patients, 
median age 56 years, underwent allogeneic HSCT from a sibling or MUD after fludarabine 
and 2 Gy TBI. Twenty-five patients were Ph+ ALL. Eighteen of these patients received post-
grafting imatinib. With a median follow-up of 43 months, the 3-year overall survival was 
34%. The 3-year relapse/progression and non-relapse mortality rates were 40% and 28%, 
respectively. Three-year OS for patients with Ph- ALL in CR1 and beyond was 52% and 8%, 
respectively. For patients with Ph+ ALL in CR1 who received post-grafting imatinib, the 3-
year OS was 62%; for the subgroup without evidence of MRD at transplantation, the overall 
survival was 73%. 
Data from the pediatric population also suggests that RIC might be a viable option. 
Verneris et al reported on 38 pediatric patients median age of 12 years who received a RIC 
allogeneic HSCT.99 Only 13% of the patients were in CR1. A third of the patients received 
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MUD transplantation. At 3 years, the probability of TRM was 40%, relapse 37%, and DFS 
was 30%. 
These results show consistently that OS is not decreased with RIC when compared to fully 
myeloablative regimens. The improved tolerability of RIC regimens, when compared to 
myeloablative regimens, makes RIC an option for older patients. RIC may also extend the 
option of an allogeneic HSCT to patients who would not otherwise be transplant candidates 
because of co-morbid conditions. 
8.6 Novel conditioning regimens 
Studies performed on patients with other hematological malignancies have suggested that 
with higher doses of TBI the rates of relapse are lower.32 These findings suggest that 
methods that can selectively deliver radiation to sites of leukemia without increasing 
toxicity might be of benefit. Two such radiation delivery methods are currently being 
explored, one is helical tomotherapy and the other is utilization of tumor-reactive 
monoclonal antibody (MAB) conjugated with locally acting radionucleotides such as Iodine-
131 or yttrium-90. 
8.7 Radioimmunotherapy 
A phase I trial of iodine-131 MAB plus Cy and TBI for advanced leukemia looked primarily 
at the biodistribution and toxicity of escalating doses of targeted radiation therapy 
combined with 120 mg/kg Cy and 12 Gy TBI followed by matched related or autologous 
HSCT.100 A total of 44 patients were included in this study, 10 had ALL, 5 of which had ALL 
in relapse or refractory disease. Five of the patients were in CR2 or third CR. The study 
demonstrated that by utilizing iodine-131 anti-CD45 MAB, appreciable supplemental doses 
of radiation could be delivered to the marrow (approximately 24 Gy) and spleen when 
combined with conventional fractionated TBI. 
Bethge et al reported a phase II study evaluating the utility of yttrium-90 as the 
radionucleotide.101 Forty patients with advanced non-Hodgkin lymphoma were enrolled 
in this study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-
tiuxetan with RIC employing fludarabine and 2 Gy TBI followed by allogeneic HSCT from 
related (n = 13) or unrelated (n = 27) donors. Median age in the study was 55 years. All 
patients were high-risk with refractory disease or relapse after preceding autologous 
HSCT.  No additional toxicity attributable to RIT was observed. Engraftment was rapid 
and sustained and estimated NRM was 45% at 2 years. Estimated 2-year OS was reported 
to be 51%. 
These early results point the way to strategy that effectively increases the intensity of the 
conditioning regimen without increased toxicity. Further study is needed to assess the 
efficacy and safety of RIT in adult patients with ALL. Other radioconjugated MAB are 
needed to target ALL as the majority do not express CD20. 
8.8 Helical tomotherapy 
Helical tomotherapy is a newer method of delivering radiation therapy. With its ability to 
focus and intensify local radiation treatment, there is potential to augment the radiation to 
the marrow containing bones without increasing toxicity to other organs. This technology 
employs a megavoltage linear accelerator mounted on a computed tomography gantry that 
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allows the beam source to continually rotate around the patient. Simultaneously, the couch, 
or patient placement device, moves perpendicularly to the beam source. The beam moves in 
a spiral or helical pattern relative to the patient. The beam can be modulated with a 
multileaf collimator. During treatment planning, these qualities allow large volumes to be 
delineated and treated, while neighboring volumes are spared.102 
Because conventional TBI can be associated with significant toxicity, there remains an 
interest in exploring helical tomotherapy as a means of delivering TBI because of its ability 
to deliver minimal radiation to sensitive organs such as the lungs and kidneys. Interstitial 
pneumonitis is an important toxicity seen with TBI and has been observed to occur in 
approximately 50% of patients receiving a single fraction of 8-10 Gy, with 50% of cases 
proving fatal.71 Even when low-dose-rate, fractionated TBI is employed with concurrent 
chemotherapy, the rate of interstitial pneumonitis may approach 25%.103 Important acute 
toxicity associated with TBI includes nausea, vomiting, parotitis, dry mouth and mucositis. 
These can be a source of significant morbidity for patients. TBI may also result in significant 
end-organ damage. Cataract formation is seen in 30-40% of patients, and gonadal failure, 
thyroid dysfunction, kidney dysfunction and decreased bone mineral density have all been 
documented.102 Survivors are also at known risk for chronic oral and dental complications 
especially xerostomia which greatly affects quality of life. Other long term complications 
may also include the development of secondary neoplasms with a 3 to 7% increase in risk at 
15 years following transplant.104, 105 Thus, hypothetically, delivering TBI via helical 
tomotherapy might minimize these complications while allowing dose escalation of 
radiotherapy to the target tissues. 
Zhuang et al reported a dosimetric comparison of TBI delivered via helical tomotherapy 
compared with the more traditional extended source to surface distance (SSD) approach.106 
Results from this study showed that the average dose delivered to the target volume was 
improved with tomotherapy while a lesser dose was delivered to the lungs, which were 
excluded from the target volume. Another similar study evaluated the use of tomotherapy 
to treat the marrow cavity (target region skeletal bone) as well as the major lymph node 
chains, spleen and sanctuary sites.107 A 1.7 to 7.5-fold reduction in median organ dose was 
demonstrated and a dose-volume histogram analysis predicted that dose escalation up to 20 
Gy was feasible and potentially safe with this technique. 
Penagaricano et al reported the utility of TBI with helical tomotherapy in patients with 
AML.108 Four patients with AML received TBI by tomotherapy as part of their conditioning 
regimen prior to allogeneic transplantation. They each received 12 Gy in six equal fractions 
at two fractions per day, over 3 days. TBI planning was set up so that the lungs and kidneys 
would receive minimal radiation. Analysis showed that although the delivered clinical 
target volume doses ranged from 11.9 to 12.3 Gy, the delivered lung doses ranged from 6.5 
to 7.4 Gy and the delivered kidney doses ranged from 7.2 to 8.6 Gy. Overall toxicity was 
limited to grade I asymptomatic radiation dermatitis and grade I headache. 
These studies have demonstrated the feasibility of helical tomotherapy to deliver TBI. 
Tomotherapy delivers an elegant and dosimetrically superior solution to the conventional 
technique of TBI. With tomotherapy, there is no need for blocks or compensators, low dose 
rates, extended source to skin distances, beam spoilers or uncomfortable patient positioning. 
Further investigation in this area might allow delivery of higher doses of radiation to sites of 
disease while limiting exposure to critical structures and thus reducing toxicity and long-
term complications. 
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9. Conclusion 
Allogeneic HSCT remains integral to the treatment of adult patients with ALL. Preliminary 
evidence supports the use of alternative donors in HSCT for ALL. As in other forms of 
hematological malignancy the use of fully matched unrelated donors shows similar outcome 
to matched related donor HSCT in patients with ALL. The use of UCB as the donor source 
appears feasible in children and also in adults. Whether the use of less well matched donors, 
such as haploidentical siblings, or unrelated multiple UCB units has utility in the treatment 
of ALL needs further study of efficacy but is certainly feasible. 
The UKALL XII/ECOG E2993 trial confirmed the presence of GVL in allogeneic HSCT for 
ALL. It also showed that the benefit of allogeneic HSCT was operative in standard-risk ALL. 
Surprisingly, the benefit of allogeneic HSCT was not clearly demonstrated in patients with 
high-risk ALL, but was certainly not inferior to other therapy. Autologous HSCT proved 
inferior to allogeneic HSCT and chemotherapy only treatment. Despite these findings the trial 
has been the focus of much debate and alternative analyses have been presented that question 
the magnitude of the benefit from allogeneic HSCT. Nevertheless we conclude that allogeneic 
HSCT should be included as a therapeutic option for all patients with ALL eligible for HSCT. 
The applicability of pediatric style chemotherapeutic regimens to adult patients is currently 
under investigation. If these regimens can be safely administered to adult patients and yield 
improved results particularly in the AYA population, then the benefit from GVL might be 
reduced negating the need for allogeneic HSCT in first remission. 
Ph+ ALL presents a unique therapeutic opportunity with TKIs such as imatinib, nilotinib 
and dasatinib. The combination of TKIs and chemotherapy has been demonstrated to be 
feasible and they may also be effectively administered after both autologous and allogeneic 
HSCT. The utility of allogeneic transplantation will need to be tested again in Ph+ ALL, if 
recently conducted studies show superiority of TKIs in combination with chemotherapy 
over historical data. 
Moreover, the expanded use of MRD monitoring and a better understanding of its utility 
might further refine selection of patients who would benefit from allogeneic HSCT. 
Innovative approaches to conditioning regimens including RIC, radioimmunoconjugates and 
helical tomotherapy offer the possibility of reduced toxicity and thus wider applicability of 
HSCT. The more elderly patient with ALL might then become a candidate for allogeneic HSCT 
with consequent improvement in survival. In younger patients the ability to escalate the 
intensity of the conditioning regimen might improve disease control without adding to toxicity. 
The treatment of adult ALL has improved but remains inferior to the results seen in the 
pediatric population. Further research into the biological diversity of ALL may help explain 
this difference and allow therapy to be tailored to individual circumstance. Ultimately only 
well designed and conducted clinical trials will allow us to address these questions and 
refine therapy. Given the relative rarity of this disease, international collaboration remains 
the most efficient way of obtaining timely answers to questions surrounding the treatment 
of adult ALL. 
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